Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation (MTR).
More Telix Pharmaceuticals content >Investment summary
Telix is developing diagnostic and therapeutic radiopharmaceuticals for kidney, prostate and brain cancers. Its molecularly targeted radiation (MTR) potentially offers better informed treatment decisions and personalized therapy. Its lead product Illuccix (TLX591) for prostate cancer imaging has been filed in the United States and Europe. Telix expects to fully enrol the ZIRCON Phase III for kidney cancer imaging agent TLX250-CDx in 2021.
Y/E Dec |
Revenue (A$m) |
EBITDA (A$m) |
PBT (A$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 15.2 | (24.3) | (31.1) | (11.94) | N/A | N/A |
| 2020A | 17.5 | (39.3) | (47.9) | (17.45) | N/A | 860.5 |
| 2021E | 23.6 | (41.4) | (45.9) | (15.74) | N/A | N/A |
| 2022E | 33.6 | (41.1) | (46.0) | (15.17) | N/A | N/A |
Industry outlook
Big pharma has shown keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US$3.9bn. In 2014 Bayer acquired Algeta for ~US$2.6bn; Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. In December 2018 Novartis acquired prostate cancer radiopharmaceutical developer, Endocyte for US$2.1bn.
Last updated on 21/09/2021Content on Telix Pharmaceuticals
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (A$m) | 22.5 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Christian Behrenbruch | CEO |
| Douglas Cubbin | CFO |